25,474 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 25,474 shares of the biopharmaceutical company’s stock, valued at approximately $15,884,000.

Several other institutional investors have also recently bought and sold shares of REGN. California State Teachers Retirement System boosted its stake in Regeneron Pharmaceuticals by 63,274.2% in the second quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company’s stock worth $60,934,625,000 after purchasing an additional 97,569,482 shares in the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at $74,000. Wedmont Private Capital increased its stake in shares of Regeneron Pharmaceuticals by 9.3% in the second quarter. Wedmont Private Capital now owns 1,310 shares of the biopharmaceutical company’s stock valued at $871,000 after buying an additional 112 shares in the last quarter. Saudi Central Bank raised its holdings in shares of Regeneron Pharmaceuticals by 90.8% in the second quarter. Saudi Central Bank now owns 7,273 shares of the biopharmaceutical company’s stock valued at $4,535,000 after buying an additional 3,461 shares during the last quarter. Finally, Azimuth Capital Investment Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at about $7,293,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the topic of several research reports. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Wells Fargo & Company raised their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $800.36.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,146 shares of company stock worth $3,432,488 over the last quarter. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $827.72 on Tuesday. The firm has a market capitalization of $85.22 billion, a PE ratio of 20.46, a price-to-earnings-growth ratio of 1.62 and a beta of 0.20. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $859.34. The firm’s 50-day moving average is $742.21 and its 200-day moving average is $719.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the firm posted $12.81 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.